Home Cart Sign in  
Chemical Structure| 2676211-64-4 Chemical Structure| 2676211-64-4

Structure of FHD-609
CAS No.: 2676211-64-4

Chemical Structure| 2676211-64-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FHD-609 is a BRD9 inhibitor and degrader that targets ncBAF for research in various cancers.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FHD-609

CAS No. :2676211-64-4
Formula : C47H56N8O6
M.W : 829.00
SMILES Code : C(N1CCC2(CN(C2)C=3C=C4C(=CC3)CN(C4=O)[C@@H]5C(=O)NC(=O)CC5)CC1)C6CCN(CC7=C(OC)C=C(C=C7OC)C=8C=9C(=CN=C(C9)N%10CCC%10)C(=O)N(C)C8)CC6
MDL No. :N/A

Safety of FHD-609

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of FHD-609

epigenetics

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04965753 Advanced Synovial Sarcoma PHASE1 TERMINATED 2023-12-04 City of Hope, Duarte, Californ... More >>ia, 91010, United States|University of Miami Health System, Miami, Florida, 33136, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37205, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Centre Leon Berard, Lyon, 69008, France|Institut Gustave Roussy, Villejuif, 94805, France|Istituto Nazionale dei Tumori, Milan, 20133, Italy|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.21mL

0.24mL

0.12mL

6.03mL

1.21mL

0.60mL

12.06mL

2.41mL

1.21mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories